Sign inJoin waitlistJoin the waitlist

Kanwal Raghav

Associate Vice President (AVP), Ambulatory Medical Operations · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

Ambulatory Treatment Centers · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2010–2013
Internal Medicine
Jefferson Health Medical Education
2003–2006
University College of Medicine
1999–2003

Research

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
JAMA Oncology · 2019 · Last of 10 authors · 485 citations
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
The Lancet Oncology · 2019 · 452 citations
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
JAMA Oncology · 2019 · 389 citations

Michael Overman
94 papers
Scott Kopetz
72 papers
Robert Wolff
47 papers
Arvind Dasari
41 papers
Van Morris
39 papers
Christine Parseghian
29 papers · 5 as a fellow
Bryan Kee
28 papers
Cathy Eng
28 papers
Funda Meric-Bernstam
24 papers
Jean-Nicolas Vauthey
21 papers
Keith Fournier
20 papers
Milind Javle
20 papers

Grants

A Technological Approach for Performance Status Assessment in Advanced Cancer Patients
National Cancer Institute · R01
PI · $3M · University of Tx Md Anderson Can Ctr
2020–2026

Clinical trials

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2029
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2023–2024
Sintilimab in Cancer of Unknown Primary
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2021–2025
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2021–2027